NYSEHealth CareMedical - DistributionSnapshot 2026-08-31
Reading CAH? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Intact: The reason to own it still holds.
Cardinal Health grows revenue about 11-19% yearly. EPS guidance rose from $9.4 to $10.75. Free cash flow guidance increased to $3.5 billion. The company has strong profit margins and solid cash flow.
EPS growth may slow if demand weakens. Free cash flow could fall short if costs rise. Competition or regulatory changes could pressure margins.
The price is about 6% below our fair value near $254. Analysts expect about 14% revenue growth. Our view aligns with the Street on growth but sees slightly better value.
Breaks if: EPS guidance falls below $9.4 next fiscal year
Breaks if: Free cash flow guidance falls below $3.25 billion next fiscal year
Breaks if: YoY revenue growth falls below 7% next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a durable compounder with a focus on consistent earnings growth and cash flow generation. The current thesis state is intact, supported by strong financial performance and management priorities.
The market appears to have priced in a level of fragility due to weak execution quality, despite CAH being relatively expensive compared to peers. The expectations gap suggests that the market is anticipating some challenges ahead.
Management is on track with its priorities, including increasing earnings guidance and expanding segment profits. Recent financial performance has been strong, but there is a low probability of missing expectations, although past misses could weigh on sentiment.
Key factors include the performance of sector bellwethers and any potential guidance cuts from CAH. Additionally, ongoing macroeconomic conditions, such as job growth, will play a significant role in shaping future performance.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company beat earnings expectations in its latest report. It also guided for 13-15% earnings growth for fiscal 2027. This guidance is above the consensus estimate of $12.04. The outlook for profit in the Pharmaceutical Solutions segment is positive. There are no new threats identified that weaken the read.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, CAH's trajectory will depend on management execution and sector dynamics. Not investment advice.
